Work

Pharmacokinetics of Single-Agent Lumiliximab (Anti-CD23 Antibody) in Patients with Chronic Lymphocytic Leukemia.

Year: 2004

Type: article

Study design: Clinical Trial

Source: Blood

DOI: 10.1182/blood.v104.11.4831.4831

Authors: James Woodworth, Bryan R. Leigh, Susan O’Brien, Ian Flinn, Thomas J. Kipps, Mark A. Weiss, Kanti Rai, Aron Thall, Dee Wynne, John C. Byrd

Institutions: Biogen (United States), The University of Texas MD Anderson Cancer Center, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, University of California San Diego, Memorial Sloan Kettering Cancer Center, Long Island Jewish Medical Center, The Ohio State University

Language: English

Topic: Chronic Lymphocytic Leukemia Research

Subfield: Genetics (clinical)

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2536172490

FWCI: 0.348

Cites:

Cited by: 3

Related to: 10